We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Nancy
Preston
n.j.preston@lancaster.ac.uk
Rachel
Hooley
r.leech2@lancaster.ac.uk
Nancy
Preston
n.j.preston@lancaster.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Persons encountering health services for specific procedures and health careMalignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Many patients with advanced cancer in the final phase of life leave the hospital without continuity of information, and certainty about further treatment and care provision. Often, communication between healthcare providers in different settings is suboptimal and this leads to poor continuity and coordination of care, negatively impacting the quality of life and increasing preventable hospital admissions.
The PAL-CYCLES programme is a transitional palliative care programme for patients with advanced cancer, adaptable to local cultures and healthcare systems. The programme contains an intervention aiming for a smooth transition from hospital care to community care, consisting of five cornerstone components: (1) identification of a patient with palliative and supportive care needs in collaboration with the oncologist and the hospital palliative care team; (2) compassionate communication towards the patient and their family; (3) a collaborative multidimensional care plan and follow-up in the home care setting; (4) periodic evaluation of the care plan with patients and relatives; (5) identification of the terminal phase (if there) based on the periodic evaluations, with appropriate intensification of care and end-of-life talks depending on local possibilities and habits, including consultation with patient and families about ethically and legally sensitive issues. Plan: we intend to implement and evaluate the PAL-CYCLES programme in seven European countries using a stepped wedge randomised controlled trial design. Patient, relatives, and health care provider experiences, as well as ethical and equity issues will be addressed with qualitative methods.
The PAL-CYCLES programme will facilitate patient-centred communication and continuity of palliative cancer care in the community care setting, reducing unplanned hospital admissions and improving quality of life for patients with advanced cancer at the end of life.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Management of Care;
You can take part if:
You may not be able to take part if:
Patients (control and intervention) Exclusion criteria: • People with cancer unable or unwilling to provide consent to participate in the study • We will not recruit participants who are already involved in another research project. This will be checked by the research nurse by checking the patients medical records. Relatives (control and intervention): • People unable or unwilling to provide informed consent to participate in the study
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Nancy
Preston
n.j.preston@lancaster.ac.uk
Nancy
Preston
n.j.preston@lancaster.ac.uk
Rachel
Hooley
r.leech2@lancaster.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by University of Lancaster and funded by UK Research and Innovation (UKRI) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 60114
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
